Waters Corp Earnings Call: Growth, Risks and Synergies
Waters Corp ((WAT)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Waters Corp’s latest earnings call struck a cautiously upbeat tone, blending strong core execution and product-led growth with a frank acknowledgment of near-term headwinds. Management underscored robust cash generation, expanding margins and a transformative acquisition, while stressing that conservative baselines and detailed synergy plans leave room for upside if integration and commercial initiatives land as planned.
Q4 Revenue Beat Anchored by EPS Outperformance
Waters reported Q4 sales of $932 million, rising 7% on a reported basis and 6% in constant currency, as recurring revenue climbed 9% and underpinned margins. Adjusted EPS reached $4.53 versus GAAP EPS of $3.77, signaling solid profitability even as certain instrument segments lagged and mix effects remained in play.
Full-Year Growth, Margin Strength and Cash Generation
For the full year, revenue expanded 7% both reported and in constant currency, while adjusted EPS advanced 11% to $13.13 compared with GAAP EPS of $10.76. Gross margin landed at 59.3% and adjusted operating margin at 30.5%, with free cash flow of $677 million providing ample flexibility for investment, acquisitions and planned deleveraging.
Recurring Revenue and LC‑MS Engines Drive Core Momentum
Recurring revenue rose 8% for the year, with service up 7% and chemistry up a robust 12%, reinforcing the stickiness of the installed base. Instrument revenue grew 5% as LC‑MS platforms delivered high single-digit growth or better every quarter, cementing their role as a structural growth engine despite softness elsewhere.
Improving Commercial KPIs and Expanding E‑Commerce Channel
Service plan attachment climbed to 54%, roughly 400 basis points higher year over year, while instrument replacement has been tracking at about a 2.5% CAGR versus 2019. E‑commerce now accounts for around 45% of consumables revenue, and contract organizations have grown to 27% of pharma sales, up sharply from 15% five years ago.
Product Innovation Fuels High-Growth Niches
New products are clearly resonating, with Alliance iS HPLC sales more than doubling and Xevo TQ Absolute platforms growing over 30%. MaxPeak Premier chemistry exceeded 35% growth, while broader chemistry and bioseparations offerings, including SEC columns, slalom chromatography and affinity separations, are expected to post double-digit expansion in 2025.
Transformative BD Acquisition with Defined Synergy Roadmap
Waters closed its acquisition of the BD Biosciences & Diagnostic Solutions business, which is expected to add about $3.0 billion of revenue in 2026. The company is targeting roughly $55 million of cost synergies and $50 million of revenue synergies, supporting a combined 2026 adjusted operating margin of about 28.1% and adjusted EPS of $14.30 to $14.50.
Strong Free Cash Flow and Deleveraging Commitment
Fourth-quarter free cash flow came in at $125 million after $39 million of capex, contributing to full-year free cash flow of $677 million after $113 million of capex. Pro forma net debt is expected at roughly $4.6 billion to $4.7 billion, or about 2.4 times net debt to EBITDA, with management outlining a clear path to bring leverage below 2 times within roughly 18 months.
BD Underperformance Highlights Near-Term Integration Risk
The newly acquired BD businesses underdelivered in Q4, hurt by weaker China demand linked to diagnostics consumption cuts and reimbursement dynamics, U.S. export delays tied to government disruptions and a mild flu season hitting point-of-care volumes. Management is baking in only about 2.5% underlying growth for the unit in 2026 and expects a low single-digit revenue decline from the partial Q1 contribution of roughly $480 million.
TA Instruments Weakness Weighs on Instrument Growth
TA Instruments remained a soft spot, declining in the quarter amid cautious capital spending in the U.S. and Europe and finishing the year down about 1%. As a result, overall instrument sales grew just 3% in Q4, with TA acting as a drag on what would otherwise be healthier instrument momentum driven by LC‑MS and chromatography.
Academic, Government and Regional Pressures Persist
Academic and government demand fell 3% in Q4 and about 1% for the full year, with Europe particularly weak at roughly a 5% decline for the year in that segment. China also showed pockets of fragility tied to the timing of stimulus and ongoing reimbursement-related headwinds, adding another layer of macro uncertainty to the growth outlook.
Empower Subscription Shift Creates Short-Term Revenue Noise
The transition of the Empower platform to a subscription model shaved a low-single-digit percentage off instrument growth in the quarter, as revenue is now recognized over the life of contracts. Management views this as a strategic move to deepen recurring revenue, but investors should expect some short-term timing distortion and evolving revenue recognition patterns.
Higher Leverage, Interest Expense and Shares Temper EPS
The acquisition lifts pro forma net debt to around $4.6 billion to $4.7 billion and brings projected 2026 net interest expense to about $179 million, raising the financial burden versus prior periods. A larger share count of roughly 98.4 million at close and about 94.3 million on a full-year average will dilute EPS optics in the near term, even though the deal is still projected to be modestly accretive.
Guidance Signals Steady Core Growth with Acquisition Upside
Waters guided stand-alone 2026 organic constant-currency revenue growth of 5.5% to 7%, plus a modest foreign-exchange tailwind, and expects the BD businesses to deliver about $3.0 billion of revenue with incremental synergies. This underpins total 2026 revenue of $6.405 billion to $6.455 billion, an adjusted operating margin of roughly 28.1% and adjusted EPS of $14.30 to $14.50, with Q1 revenue of about $1.198 billion to $1.211 billion and EPS of $2.25 to $2.35.
Waters’ earnings call painted a picture of a company leaning on strong recurring revenue, innovation and disciplined cash management as it digests a large acquisition and battles selective market softness. While underperformance in the acquired BD businesses, TA weakness and higher leverage add execution risk, the detailed synergy plan and solid core growth guidance suggest meaningful upside if management delivers on its integration and commercial playbook.
